Jidan Biotech: 2025 Annual Shareholders Meeting Materials

Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

Nanjing, China

2026 May Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials Jidan Biotechnology Co., Ltd.

2025 Annual General Meeting of Shareholders Meeting Materials Catalog Serial Number Meeting Material Name

1 Instructions for the 2025 Annual Shareholders' Meeting of Jidan Biotechnology Co., Ltd. 2 Agenda for the 2025 Annual Shareholders' Meeting of Jidan Biotechnology Co., Ltd. 3 Proposals and reports heard at the 2025 Annual Shareholders' Meeting of Jidan Biotechnology Co., Ltd. Proposal 1 Proposal on the company's "2025 Annual Report" and its summary

Proposal 2 Proposal on the company's "2025 Board of Directors Work Report"

Proposal 3 Proposal on the company’s profit distribution plan for 2025

Proposal 4 Proposal on requesting the shareholders meeting to authorize the Board of Directors to formulate and implement the 2026 interim dividend plan Proposal 5 Proposal on the remuneration of the company’s directors and senior managers

Proposal 6 Proposal on using self-owned idle funds for investment and financial management

Proposal 7 Proposal on the company and its wholly-owned and controlled subsidiaries applying for a comprehensive credit line from the bank Proposal 8 Proposal on the renewal of the accounting firm

Proposal 9 Proposal on the establishment of corporate governance-related systems

Proposal 10 Report on the company's shareholder return plan for the next three years (2026-2028) "Jidan Bio: 2025 Independent Directors' Work Report"

Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

Jidan Biotechnology Co., Ltd.

Instructions for the 2025 Annual Shareholders Meeting

In order to safeguard the legitimate rights and interests of all shareholders, ensure the normal order and efficiency of the shareholders' meeting of Jidan Biotechnology Co., Ltd. (hereinafter referred to as "Jidan Biotechnology" or the "Company"), and ensure the smooth progress of the shareholders' meeting, in accordance with the provisions of the "Company Law of the People's Republic of China", "Securities Law of the People's Republic of China", "Articles of Association of Jidan Biotechnology Co., Ltd." and "Rules of Procedure for the Shareholders' Meeting", the following instructions are formulated for this shareholders' meeting:

1. Shareholders who participate in shareholders’ meetings should conscientiously perform their legal obligations and must not infringe on the rights and interests of other shareholders;

2. Shareholders and shareholders' agents attending the on-site shareholders' meeting should present or submit their ID cards or other valid certificates or certificates that can show their identity, a copy of the corporate business license with the official seal of the legal person (for legal person shareholders), a power of attorney (for shareholder agents), shareholding certificates and other documents when going through the meeting registration procedures;

3. Shareholders attending the meeting enjoy various rights such as the right to speak, the right to consult, and the right to vote in accordance with the law. Shareholders who request to speak must register with the company's meeting affairs team in advance. After registration, the order of shareholders' speeches will be in the order of time when the registration form is submitted;

4. In order to ensure the normal conduct of the meeting, in principle, each shareholder shall not speak more than 2 times, and the total speaking time shall not exceed 3 minutes in principle. When shareholders ask questions, the meeting host can designate relevant personnel to answer on their behalf. The relevant personnel shall not answer the questions for more than 3 minutes. The content of the speech must focus on the motion. The meeting host may refuse to answer questions unrelated to the content of the motion at this meeting. When the shareholders' meeting enters the voting process, shareholders are not allowed to speak or ask questions;

5. All resolutions at this meeting will be voted by registered ballot. All resolutions at this meeting are non-cumulative voting resolutions. Each vote should be "Agree" or "No" or "Abstain". Only one column can be filled in for each vote. Multiple selections or no selections will be deemed as the voter giving up the right to vote, and the voting results of the number of shares held will be treated as invalid votes. Please fill in the blank column with a "√" symbol when voting; each voting ticket must be signed by the voter (shareholder or agent). Any unsigned vote will be regarded as the voter giving up the right to vote, and the voting results of the number of shares held will be treated as invalid votes;

6. In order to ensure the solemnity and normal order of the meeting and effectively protect the legitimate rights and interests of shareholders (or shareholders’ agents) attending the meeting, except for shareholders (or shareholder representatives) attending the meeting, company directors, senior managers, intermediaries hired by the company, and persons invited by the board of directors, the company has the right to refuse other people from entering the venue in accordance with the law; Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

7. The entire meeting will be audio-recorded and videotaped. Personal recording, photography and video recording are prohibited. In order to maintain the order of the venue, please do not make loud noises in the venue, and any behavior that disrupts the normal order of the meeting is prohibited. The staff has the right to take measures to stop any behavior that interferes with the meeting, provokes troubles and infringes on the legitimate rights and interests of other shareholders, and reports to the relevant departments for investigation and punishment in a timely manner. Please turn off your mobile phone or set it to vibrate during the meeting.

Board of Directors of Jidan Biotechnology Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Jidan Biotechnology Co., Ltd. on May 22, 2026

Jidan Biotechnology Co., Ltd.

2025 Annual Shareholders Meeting

meeting agenda

1. On-site meeting time: 14:00 on May 22, 2026 (Friday)

2. Online voting system and voting time: Online voting is conducted through the Shanghai Stock Exchange Shareholders Meeting online voting system. The start and end time of online voting is from May 22, 2026 to May 22, 2026. The Shanghai Stock Exchange online voting system is adopted, and through the trading system The voting time of the unified voting platform is the trading time period on the day of the shareholders’ meeting, that is, 9:15-9:25, 9:30-11:30, 13:00-15:00; the voting time of the Internet voting platform is 9:15-15:00 on the day of the shareholders’ meeting.

3. On-site meeting location: Conference Room of Jidan Biotechnology Co., Ltd., No. 9 Bofu Road, Yanjiang Industrial Development Zone, Liuhe District, Nanjing City

4. Meeting Convener: Company Board of Directors

5. Meeting host: Chairman Mr. Su Enben

6. Meeting method: a combination of on-site meetings and online voting

7. Participants

(1) Shareholders of the company registered in the Shanghai Branch of China Depository and Clearing Co., Ltd. as of the close of trading on May 18, 2026 (Monday) have the right to attend the shareholders' meeting, and can entrust a proxy in writing to attend the meeting and vote. The proxy does not have to be a shareholder of the company.

(2) Company board members and senior managers

(3) Lawyers hired by the company

(4) Other persons invited by the company’s board of directors

8. Meeting Agenda

(1) Directors and senior managers participating in the on-site meeting shall sign in and register, and shareholders and shareholders’ agents present at the meeting shall sign in and register and speak.

(2) The on-site meeting officially starts at 14:00, and the secretary of the board of directors reports on the attendance of shareholders at the meeting

(3) The host of the meeting announced the start of the shareholders' meeting, and each speaker read out the motions. After all the motions were read out, the "2025 Independent Directors' Work Report" was heard.

(4) Introduce on-site attendance, terminate meeting registration, and announce the number of voting shares present at the meeting. 2025 Annual Shareholders Meeting Materials of Jidan Biotechnology Co., Ltd.

(5) Shareholders’ speeches and company directors and senior managers answering questions

(6) Announce the list of vote counters and scrutineers

(7) Voting at on-site meetings

(8) Statistics of voting results and announcement of on-site voting results

(9) Calculating the final voting results after the online voting ends

(10) Witness the lawyer reading out the legal opinion

(11) Read out the meeting resolutions, and the directors attending the meeting will sign the meeting minutes and resolutions

(12) The host announces the closing of the meeting

Board of Directors of Jidan Biotechnology Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Jidan Biotechnology Co., Ltd. on May 22, 2026

Proposal 1:

Proposal on the Company's "2025 Annual Report" and its Summary

(This proposal was reviewed and approved at the 11th meeting of the company’s fourth session of the Board of Directors held on April 29, 2026.

For details, please refer to the relevant content disclosed by the company on April 30, 2026)

Dear shareholders and shareholders’ agents:

The company prepares the "2025 Annual Report" and its summary based on the actual operating conditions and financial status in 2025 and in accordance with relevant regulations, which can comprehensively, objectively and truly reflect the company's annual operations in 2025. For details, please refer to the "Jidan Biotech: 2025 Annual Report" and its summary disclosed by the company on April 30, 2026.

This proposal is invited to be reviewed by shareholders and shareholders’ agents.

Board of Directors of Jidan Biotechnology Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Jidan Biotechnology Co., Ltd. on May 22, 2026

Proposal 2:

Proposal on the company's "2025 Board of Directors Work Report"

(This proposal was reviewed and approved at the 11th meeting of the company’s fourth session of the Board of Directors held on April 29, 2026.

For details, please refer to the relevant content disclosed by the company on April 30, 2026)

Dear shareholders and shareholders’ agents:

In 2025, the board of directors of Jidan Biotechnology Co., Ltd. (hereinafter referred to as the "Company") strictly complied with the Company Law, Securities Law, Shanghai Stock Exchange Stock Listing Rules, and Shanghai Stock Exchange Self-Discipline Supervision Guidelines for Listed Companies. No. 1 - Standardized Operations" and other laws and regulations as well as the "Articles of Association", "Rules of Procedure of the Board of Directors" and other provisions. All directors, in line with the attitude of being responsible to the company and all shareholders, diligently and responsibly perform various duties, actively implement various resolutions of the shareholders' meeting, and ensure the company's standardized operations and scientific decision-making. The work report of the Board of Directors in 2025 is now as follows:

1. The company’s overall operating situation in 2025

In 2025, the company will achieve a total operating income of 1.052 billion yuan, a decrease of 9.71% over the same period last year; a total operating cost of 797 million yuan, a decrease of 10.43% over the same period last year; and a net profit of 212 million yuan, a decrease of 7.81% over the same period last year.

At the end of 2025, the company's total assets were 3.756 billion yuan, an increase of 49 million yuan or 1.31% over the same period last year.

During the reporting period, the company's main business did not change.

2. Daily work of the Board of Directors in 2025

(1) Convening of the 2025 Board of Directors Meeting

In 2025, the company held a total of 4 board meetings. The notice, convening, and voting procedures of the board of directors were all in compliance with the provisions of laws and regulations such as the Company Law, the Articles of Association, the Rules of Procedure of the Board of Directors, and the requirements of regulatory authorities. The members of the company's board of directors carefully understand and review each proposal, effectively ensuring the scientificity and rationality of the board's decision-making. The convening situation is as follows:

Serial number Meeting session Convening date Proposal to be reviewed

1. Review and approve the "About the Company's 2024 Annual Report" and its summary of the fourth session of the Board of Directors

1 Proposal on 2025/4/29"; 2. Review and approve the "About the Company's 15th Meeting of 2025"

"Quarterly Report> Proposal"; 3. Consideration and approval of "About the Company <2024 Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials"

4. Considered and approved the "Proposal on the company's 2024 Board of Directors Work Report"; 5. Considered and approved the "Proposal on the company's 2024 Independent Director Work Report"; 6. Considered and approved the "Proposal on the company's 2024 Board of Directors Audit Committee Performance Report"; 7. Considered and approved the "Proposal on the company's 2024 Financial Final Accounts Report";

5. Considered and approved the "Proposal on the Company's 2024 Internal Control Evaluation Report"; 9. Considered and approved the "Proposal on the Company's 2024 Profit Distribution Plan"; 10. Considered and approved the "Proposal on the Remuneration of the Company's Directors and Senior Management Personnel"; 11. Considered and approved the "Proposal on the Implementation of Daily Related Transactions in 2024 and 2025 12. Considered and approved the “Proposal on the use of self-owned idle funds for investment and financial management”; 13. Considered and approved the “Proposal on the Company and its wholly-owned and controlled subsidiaries’ application for comprehensive credit lines from banks”; 14. Considered and approved the “Proposal on the renewal of the accounting firm” 15. Considered and adopted the "Proposal on Self-examination of the Independence of Independent Directors"; 16. Considered and adopted the "Proposal on the Assessment Report on the Performance of Accounting Firms' Duties in 2024"; 17. Considered and adopted the "Proposal on the Audit Committee's Performance of Supervisory Responsibilities of the Accounting Firms in 2024" 18. Considered and approved the "Proposal on Convening the Company's 2024 Annual General Meeting of Shareholders"; 19. Considered and approved the "Proposal on Increasing the Company's Business Scope and Amending the Company's Articles of Association"; 20. Considered and approved the "Proposal on Provision for Asset Impairment in 2024" ; 21. Considered and adopted the "Proposal on the Special Explanation of Matters Involved in the Audit Opinions of the Board of Directors on Non-standard Financial Reports"; 22. Considered and adopted the "Proposal on the Special Explanations of the Board of Directors on Matters Involved in the Audit Opinion of Non-standard Internal Control"; 23. Considered and adopted the "Proposal on the Correction of Accounting Errors". The fourth session of the Board of Directors reviewed and approved the "Proposal on Investment and Construction of Intelligent Production R&D Bases 2" 2025/7/4

Proposal of the Sixth Meeting.

1. Considered and approved the "Proposal on the Company's 2025 Semi-annual Report and its Summary"; 2. Considered and approved the "Proposal on Cancellation of the Supervisory Board and Amending the Articles of Association"; 3. Considered and approved the "Proposal on Revising and Establishing Corporate Governance Related Systems"; 4. Considered and approved the "Proposal on the Company's 2025 Half-Year Profit Distribution Plan for the Fourth Session of the Board of Directors"; 5. 3 2025/8/29

The seventh meeting reviewed and approved the "Proposal on Convening the Company's First Extraordinary General Meeting of Shareholders in 2025"; 6. reviewed and approved the "Proposal on Provision for Asset Impairment"; 7. reviewed and approved the "Proposal on the Progress of the "Improving Quality, Efficiency and Focus on Returns" Action Plan"; 8. reviewed and approved the "Proposal on Appointment of Securities Affairs Representatives".

1. Considered and approved the fourth session of the Board of Directors’ “Report on the Company’s Third Quarterly Report for 2025”

4 2025/10/30 Proposal"; 2. Considered and approved the "Eighth Meeting on Revising and Formulating Corporate Governance Policy"

Proposal on the system”.

(2) The convening of shareholders’ meetings during the reporting period

Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

During the reporting period, the company held two shareholders' meetings, both convened by the board of directors. The board of directors organized shareholders' meetings in a standardized manner.

Convened in strict accordance with the requirements of the Company Law, Articles of Association and other relevant laws, regulations and management systems, a comprehensive

Implement the resolutions of the company's shareholders' meeting, promote the smooth implementation of various resolutions passed by the company's shareholders' meeting, and effectively maintain and protect

Protect the rights and interests of all shareholders, especially small and medium-sized shareholders. The specific situation is as follows:

Meeting session Meeting type Date of meeting Proposal to be considered

The meeting reviewed and approved the "Proposal on the Company's 2024 Annual Report" and its Summary, "Proposal on the Company's 2024 Board of Directors Work Report", "Proposal on the Company's 2024 Supervisory Board Work Report", "Proposal on the Company's 2024 Financial Final Report", "Proposal on the Company's 2024 Profit Distribution Plan", "On 2024 Annual Shares of the Company's Directors and Senior Managers" May 2025

Proposal on Annual Shareholder Member Remuneration" "Meeting on the Remuneration of Company Supervisors" on the 22nd

"Proposal" "Proposal on the use of its own idle funds for investment and financial management" "Proposal on the company and its wholly-owned and controlled subsidiaries applying for comprehensive credit lines from banks" "Proposal on the renewal of the accounting firm" "Proposal on increasing the company's business scope and amending the Articles of Association" "Proposal on requesting the shareholders' meeting to authorize the board of directors to formulate and implement an interim dividend plan"

The meeting reviewed and approved the "Proposal on Abolition of the Supervisory Board and Amendment of the Articles of Association" and "Proposal on Amending and Establishing Corporate Governance-Related Systems", which included 7 sub-proposals: "Proposal on Amending the "Rules of Procedures of the Board of Directors"" "Proposal on Amending the "Rules of Procedures of the Shareholders' Meeting"" for the first time in 2025. September 2025

Proposal of the Extraordinary General Meeting of Shareholders" "Proposal on the Abolition of the Rules of Procedure of the Supervisory Board" 15th

"Proposal", "Proposal on Amending the "Working System of Independent Directors"", "Proposal on Amending the "Related Transaction Management System"", "Proposal on Amending the "External Guarantee Management System"", "Proposal on Amending the "Accounting Firm Selection System"

(3) Duty performance of each special committee under the board of directors

The company's board of directors consists of three specialized committees: the Audit Committee, the Strategy Committee, and the Nomination, Remuneration and Appraisal Committee.

committee. Each special committee operates in accordance with the terms of reference stipulated in the working rules of the special committee of the board of directors.

Perform duties conscientiously and provide professional advice to the board of directors for scientific decision-making. During the reporting period, the Audit Committee of the Board of Directors

It held 3 meetings, the Strategy Committee of the Board of Directors held 1 meeting, and the Nomination, Remuneration and Appraisal Committee of the Board of Directors held 1 meeting.

One meeting was held, and each special committee had no objections to the matters reviewed.

The company's board of directors has an audit committee. The audit committee has a detailed understanding of the company's financial status and operating conditions. Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Information

Mainly responsible for the communication, supervision and verification of the company's internal and external audits, promoting the company to establish effective internal controls and provide true, accurate and complete financial reports. The company's audit committee strictly follows the requirements of the company's "Implementation Rules for the Audit Committee of the Board of Directors" and gives full play to its audit and supervisory role. During the reporting period, a total of 3 meetings were held and 18 proposals were reviewed.

The Nomination, Remuneration and Appraisal Committee reviews the qualifications of the company’s directors and senior managers, selects and makes recommendations on the selection criteria and procedures, and studies and makes recommendations on the remuneration and appraisal of directors and senior managers. The company's Nomination, Remuneration and Appraisal Committee conscientiously implements the requirements of the company's "Implementation Rules for the Nomination, Remuneration and Appraisal Committee of the Board of Directors" and continuously optimizes the assessment and evaluation system for directors and senior managers. During the reporting period, the Company’s Nomination, Remuneration and Appraisal Committee convened once and reviewed one proposal.

The Company's Strategy Committee is mainly responsible for researching and making recommendations on the company's long-term development strategies and major investment decisions, comprehensively considering the uncertain factors that may exist or be faced by the company's internal and external strategic environment and operating environment, reasonably avoiding strategic risks and fully seizing strategic opportunities through effective strategic management, and ensuring the company's continued and steady development and standardized operations in the future. During the reporting period, the Company's Strategy Committee convened once and reviewed three proposals.

(4) Duty performance of independent directors

During the reporting period, the company's independent directors strictly performed their duties in accordance with relevant laws and regulations and the provisions of the "Articles of Association", "Independent Director Work System" and other internal control documents, maintained good communication with other directors and senior managers of the company, had an in-depth understanding of the company's operations, gave full play to their professional advantages and independent role, worked diligently and conscientiously, proactively understood the company's production and operation conditions, carefully reviewed every proposal, and actively provided valuable professional opinions and suggestions for the company's board of directors' decision-making. During the reporting period, the company's independent directors raised no objections to matters considered by the company's board of directors.

(5) Company information disclosure

During the reporting period, the company conscientiously performed its information disclosure obligations in accordance with the provisions of the Company Law, Securities Law, Shanghai Stock Exchange Stock Listing Rules and other laws and regulations, as well as the Articles of Association, strictly required the quality of information disclosure, disclosed information in a timely, accurate and complete manner, and did a good job of confidentiality before information disclosure to ensure that investors can understand the company's major events fairly, fairly, timely and accurately, and provide reference for their investment decisions. During the reporting period, a total of 5 periodic reports and 48 temporary announcements were disclosed through the Shanghai Stock Exchange website. There are no false records, misleading statements or major omissions in the company's information disclosure. The company's 2024 information disclosure rating is C.

(6) Investor relations management

During the reporting period, the company attached great importance to investor relations management and fully respected and maintained the interests of investors. Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

Legitimate interests. In order to enhance communication with investors, the board of directors organized three performance briefings, including the "2024 and the first quarter of 2025 performance briefing", the "2025 semi-annual performance briefing" and the "2025 third quarter performance briefing", to actively answer questions for investors so that investors can better understand the company's operations. Investors can also communicate with the company through the investor phone number, IR email, Shanghai Stock Exchange E interactive platform, etc. The company regards investor relations as a long-term and continuous work, has formed a good mutual trust and interactive relationship with investors, answers questions that public investors are concerned about, and effectively protects the investors’ right to know.

3. Priorities of the Board of Directors in 2026

In 2026, the Board of Directors will do a solid job in its daily work and make scientific and efficient decisions on major matters. The company will conscientiously implement and implement the spirit of the State Council's "Opinions on Further Improving the Quality of Listed Companies" document, further strengthen the construction of the company's board of directors, actively play the core role of the board of directors in corporate governance, implement various resolutions of the shareholders' meeting, perform duties diligently, and effectively safeguard the interests of all shareholders, especially small and medium-sized shareholders. In accordance with the established business goals and development direction, the board of directors will strive to promote the implementation of the company's development strategy, improve the construction of the company's internal control system, and ensure the company's sustainable and healthy development. At the same time, the board of directors will also vigorously promote the following work:

(1) Do a solid job in the daily work of the board of directors

The board of directors will conscientiously organize and convene meetings of the board of directors and shareholders' meeting to ensure the legal compliance of the convening, convening and voting procedures of the board of directors and shareholders' meetings, strictly implement the resolutions of the shareholders' meeting, and actively promote the implementation of the resolutions of the board of directors. At the same time, we will give full play to the supervisory role of independent directors in the company's operations, decision-making, major matters, etc. to promote the company's sustainable and healthy development; we will better utilize the functions of the special committees of the board of directors to provide more decision-making basis for the board of directors to improve decision-making efficiency and the company to improve its governance level.

(2) Improve the quality of information disclosure and strengthen investor relations management

The company's board of directors will continue to strictly comply with the requirements of the "Company Law", "Securities Law" and "Measures for the Administration of Information Disclosure of Listed Companies", in line with the principles of fairness, justice and openness, perform information disclosure obligations in accordance with the law, do a good job in information disclosure, prepare and disclose the company's regular reports and temporary announcements in a timely manner, and ensure that the company's information disclosure content is true, accurate, complete, timely, fair, concise, clear and easy to understand. The board of directors will establish a long-term, stable and good interactive relationship between the company and investors, strengthen communication with investors, improve the company's information transparency, continuously improve the level of investor relations management, and establish a good market image of the company.

(3) Improving the level of corporate governance

The board of directors will follow the relevant provisions of the Company Law, Securities Law and Articles of Association, take maximizing the interests of the company and shareholders as its code of conduct, perform its duties diligently, strengthen the obligations and responsibilities of directors, and continue to improve Dongjidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

We will actively organize and participate in various trainings to improve the standardization of work, improve business capabilities, improve the strategic decision-making ability of the board of directors, further improve the system construction of the shareholders' meeting and the board of directors, and improve the company's corporate governance level.

At the same time, the company's board of directors will also continue to improve the internal control system, improve and supplement the internal control system, strengthen the management and control of compliance construction in financial management, internal audit, risk management and other aspects, effectively implement the company's internal control system, establish a scientific and effective decision-making mechanism, and promote the sustainable, stable and healthy development of the company's production and operation.

Board of Directors of Jidan Biotechnology Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Jidan Biotechnology Co., Ltd. on May 22, 2026

Proposal three:

Proposal on the company’s profit distribution plan for 2025

(This proposal was reviewed and approved at the 11th meeting of the company’s fourth session of the Board of Directors held on April 29, 2026.

For details, please refer to the relevant content disclosed by the company on April 30, 2026)

Dear shareholders and shareholders’ agents:

Based on good expectations for the company's future development, comprehensive consideration of the company's overall operating conditions, and on the premise of ensuring the company's normal operation and long-term development, in order to repay all shareholders and allow all shareholders to share the company's operating results, the company's board of directors proposed to use the total share capital on the equity registration date for equity distribution as the base (the specific date will be clarified in the equity distribution implementation announcement. If the company's total equity changes before the equity distribution registration date, it is planned to maintain the total distribution amount unchanged, and adjust the per share distribution ratio accordingly). The company will distribute a cash dividend of RMB 1.5 (including tax) per share. Based on the total share capital of 507,153,517 shares on the trading day before the 11th meeting of the fourth board of directors (i.e. April 28, 2026), the company needs to distribute a total cash dividend of RMB 76,073,027.55 (including tax).

During the reporting period, the company distributed a total of RMB 121,716,844.08 in cash dividends (including the 2025 semi-annual dividend), accounting for 55.16% of the net profit attributable to shareholders of listed companies in the consolidated statement for that year.

This proposal is invited to be reviewed by shareholders and shareholders’ agents.

Board of Directors of Jidan Biotechnology Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Jidan Biotechnology Co., Ltd. on May 22, 2026

Proposal 4:

Regarding the proposal to the shareholders’ meeting to authorize the board of directors to formulate and implement

Proposal for the 2026 Interim Dividend Plan

(This proposal was reviewed and approved at the 11th meeting of the company’s fourth session of the Board of Directors held on April 29, 2026.

For details, please refer to the relevant content disclosed by the company on April 30, 2026)

Dear shareholders and shareholders’ agents:

In accordance with the provisions of the "Company Law", "Listed Company Supervision Guidelines No. 3 - Cash Dividends of Listed Companies", "Guidelines on the Articles of Association of Listed Companies" and other relevant laws and regulations, normative documents and the "Articles of Association", in order to safeguard the company's value and shareholders' rights and enhance investors' sense of gain, combined with the company's actual situation, the company's board of directors requested the shareholders' meeting to authorize the board of directors to formulate and implement the 2026 interim dividend plan. The basic situation is as follows:

1. Prerequisites for mid-term dividend distribution

1. The company will continue to make profits during the corresponding period in the mid-term of 2026, and the accumulated undistributed profits will be positive;

2. The company's cash flow can meet the capital needs for normal operating activities and sustainable development.

2. The upper limit of the amount of interim dividends

The company's 2026 interim cash dividend amount will not exceed the net profit attributable to shareholders of the listed company during the corresponding period.

3. Timetable for mid-term dividends

The company will implement an interim dividend after the disclosure of the 2026 semi-annual report or third quarter report based on actual operating conditions.

4. Authorization of interim dividends

In order to simplify the dividend process, the company's board of directors requested the shareholders' meeting to authorize the board of directors to decide on the 2026 interim dividend plan on the premise of meeting the above-mentioned interim dividend conditions and the upper limit of the amount, including but not limited to deciding whether to conduct an interim dividend, formulating an interim dividend plan, and implementing the specific amount and time of the interim dividend.

5. Authorization period for interim dividends

The authorization period starts from the date of review and approval at the 2025 Annual Shareholders Meeting and ends on the date when the above authorization matters are completed.

This proposal is invited to be reviewed by shareholders and shareholders’ agents.

Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

Board of Directors of Jidan Biotechnology Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Jidan Biotechnology Co., Ltd. on May 22, 2026

Proposal 5:

Proposal on the remuneration of the company’s directors and senior managers

(This proposal has been reviewed and approved at the eleventh meeting of the fourth session of the board of directors of the company held on April 29, 2026.

However, please refer to the relevant content disclosed by the company on April 30, 2026 for details)

Dear shareholders and shareholders’ agents:

Based on the company's actual operating conditions, individual work performance and contributions, as well as industry salary levels and other comprehensive factors, the company will confirm the 2025 salary situation of directors and senior managers and formulate a 2026 salary plan, as follows:

1. Confirm the remuneration situation of the company’s directors and senior managers in 2025

In 2025, the company's independent directors will implement an annual allowance system. The allowance standard for independent directors is 100,000 yuan per person per year (before tax); the company's non-independent directors do not receive director position allowances from the company based on their position as directors, and their salary standards are determined based on the specific positions they hold in the company; the company's senior managers are assessed based on their specific positions held in the company. The total remuneration of the company's directors and senior managers in 2025 is 5.6803 million yuan, as follows: Total pre-tax remuneration received from the company during the reporting period Name Position

(10,000 yuan)

Su Enben Chairman and General Manager 174.60

Tao Aidi Director 0

Su Enkui Director 43.56

Kong Tingting Director, Deputy General Manager 58.20

Yan Bin Director, Deputy General Manager 108.60

Li Jing Employee Representative Director 17.00

Wansuiren Independent Director 10.00

Ju Jixian Independent Director 10.00

Linghua Independent Director 10.00

Ni Wen Director (resigned), Chief Financial Officer 90.60

Liu Cong Secretary of the Board of Directors (resigned) 45.48

Tang Xu Secretary of the Board of Directors 0

Total - 568.03

Note:

1. The total pre-tax remuneration received from the company during the reporting period is the total pre-tax remuneration paid during the period when it served as director and senior management personnel during the reporting period;

Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

2. If there is any difference in the mantissa between some totals in this table and the direct sum of each detail, it is due to rounding.

2. Remuneration plan for the company’s directors and senior managers in 2026

(1) Applicable objects

The company’s directors and senior managers during the 2026 term.

(2) Applicable period

January 1, 2026 to December 31, 2026.

(3) Salary plan

1. Independent directors

The company's independent directors implement an annual allowance system. In 2026, the allowance standard for independent directors is 100,000 yuan per person per year (before tax).

2. Non-independent directors

(1) The company's non-independent directors do not receive director's position allowances from the company as directors. Their remuneration standards are determined based on their specific positions in the company and they receive remuneration in accordance with the company's relevant remuneration management system. Their remuneration mainly consists of basic salary and performance remuneration, of which the proportion of performance remuneration is in principle not less than 50% of the total basic remuneration and performance remuneration.

(2) The company will not pay remuneration to non-independent directors who do not hold concurrent positions or positions in the company.

3. Compensation plan for senior managers

Senior managers receive remuneration in accordance with the company's relevant remuneration management system based on their work scope and main responsibilities in the company. Their remuneration mainly consists of basic salary and performance remuneration, of which the proportion of performance remuneration is in principle not less than 50% of the total basic remuneration and performance remuneration.

3. Other instructions

1. The salaries and allowances of directors and senior managers are at pre-tax rates, and the personal income taxes involved will be withheld and paid by the company;

2. If the positions of the company's directors and senior managers change due to reelection, appointment, resignation during the term, etc., their remuneration will be calculated and paid based on their actual term of office;

3. The remuneration of directors and senior managers who hold specific management positions in the company shall be paid in accordance with the company's relevant remuneration management system, and a certain proportion of performance remuneration will be paid after the disclosure of the annual report and performance evaluation;

4. In addition to the above-mentioned remuneration plans, the company can adopt medium and long-term incentive measures for directors and senior managers based on operating conditions and market conditions, including equity incentives, employee stock ownership plans, etc. The specific plans will be determined separately by the company in accordance with relevant laws and regulations.

Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials This proposal is requested to be reviewed by shareholders and shareholders’ agents.

Board of Directors of Jidan Biotechnology Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Jidan Biotechnology Co., Ltd. on May 22, 2026

Proposal six:

Proposal on using self-owned idle funds for investment and financial management

(This proposal was reviewed and approved at the 11th meeting of the company’s fourth session of the Board of Directors held on April 29, 2026.

For details, please refer to the relevant content disclosed by the company on April 30, 2026)

Dear shareholders and shareholders’ agents:

In order to make full use of the company's own idle funds and improve the efficiency and profitability of fund use, without affecting the company's normal daily capital turnover and risk controllability, the company (including wholly-owned subsidiaries and holding subsidiaries) plans to use a maximum amount of its own idle funds not exceeding RMB 2.10 million for investment and financial management, of which the investment amount for purchasing medium- and low-risk financial products shall not exceed RMB 150,000. Ten thousand yuan, the investment scope includes medium and low-risk financial products (including trust products) issued by commercial banks, trust companies, securities companies, fund companies, insurance companies, asset management companies and other financial institutions; the investment amount for purchasing medium-risk and above-risk securities investment products shall not exceed 60,000 yuan Ten thousand yuan, the investment scope includes financial products, asset management plans, public funds, private securities funds issued by professional institutional investors such as commercial banks, securities companies, futures, public funds, private funds, and other investment activities recognized by the Shanghai Stock Exchange. Within the above quota, the company can recycle the investment and use it on a rolling basis. The entrustment period is effective from the date of review and approval of the company's 2025 annual shareholders' meeting until the next shareholders' meeting to review the same matters. Within the above quota and validity period, the funds can be used on a rolling basis, and the chairman of the board is authorized to sign relevant documents within the specified quota range. Specific matters will be organized and implemented by the company's finance department.

This proposal is invited to be reviewed by shareholders and shareholders’ agents.

Board of Directors of Jidan Biotechnology Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Jidan Biotechnology Co., Ltd. on May 22, 2026

Proposal 7:

About the company and its wholly-owned and controlled subsidiaries

Proposal to apply for a comprehensive credit line from the bank

(This proposal was reviewed and approved at the 11th meeting of the company’s fourth session of the Board of Directors held on April 29, 2026.

For details, please refer to the relevant content disclosed by the company on April 30, 2026)

Dear shareholders and shareholders’ agents:

Based on the overall situation of the company's operations and the needs of the company's 2026 fund use plan, the company and its wholly-owned and controlled subsidiaries plan to apply for a comprehensive credit line of RMB 2,000,000 from commercial banks in 2026, including short-term working capital loans, bank acceptance bills, commercial acceptance bills, letters of guarantee, letters of credit, etc. The above comprehensive credit period is from the date of review and approval at the company's 2025 annual shareholders' meeting to 2026 until similar matters are considered at the annual shareholders' meeting.

The above credit limit is not equal to the company's actual financing amount. The actual financing amount should be within the credit limit and based on the actual financing amount between the bank and the company. The specific financing amount will be reasonably determined based on the company's actual demand for operating funds. Within the credit period, the credit limit can be recycled.

The company's board of directors proposed that the shareholders' meeting authorize the company's chairman and his authorized representative to handle relevant business on behalf of the company within the above-mentioned credit limit based on the needs of actual operating conditions and sign relevant legal documents.

This proposal is invited to be reviewed by shareholders and shareholders’ agents.

Board of Directors of Jidan Biotechnology Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Jidan Biotechnology Co., Ltd. on May 22, 2026

Proposal 8:

Proposal on Re-appointment of Accounting Firm

(This proposal was reviewed and approved at the 11th meeting of the company’s fourth session of the Board of Directors held on April 29, 2026.

For details, please refer to the relevant content disclosed by the company on April 30, 2026)

Dear shareholders and shareholders’ agents:

The Audit Committee of the company's board of directors has investigated and evaluated the audit work of Gongzheng Tianye Accounting Firm (Special General Partnership) in 2025 and believes that the firm followed professional standards and completed various audit tasks.

In order to maintain the continuity of the company's audit work, the company plans to appoint Gongzheng Tianye Accounting Firm (Special General Partnership) (hereinafter referred to as "Gongzheng Tianye") as the company's 2026 audit agency to engage in the company's 2026 financial report audit and internal control audit and other related services. The annual financial audit fee is RMB 900,000, and the annual internal control audit fee is RMB 100,000. The basic information of the accounting firm proposed to be re-appointed is as follows:

1. Basic information

(1) Name of the accounting firm: Gongzheng Tianye Accounting Firm (Special General Partnership)

Date of establishment: Gongzheng Tianye was founded in 1982. It is one of the first accounting firms in the country approved to engage in securities, futures-related business qualifications and financial business audit qualifications. On September 18, 2013, it was transformed into a special general partnership.

Organizational form: special general partnership

Registered address: Room 5-1001, Jiaye Fortune Center, Taihu New Town, Wuxi City

Chief Partner: Zhang Caibin

(2) As of the end of 2025, the number of Notary Tianye partners is 56, the number of certified public accountants is 312, and the number of certified public accountants who have signed securities service business audit reports is 172.

(3) The total audited income of Notary Tianye in 2025 is RMB 293.0646 million, including RMB 249.8016 million from auditing business and RMB 157.0631 million from securities business. The number of audit clients for the annual reports of listed companies in 2025 is 80, and the total audit fees are 85.4862 million yuan. The main industries of listed companies include manufacturing, information transmission, software and information technology services, wholesale and retail, water conservancy, environment and public facilities management, scientific research and technical services, etc. Among them, the company has 65 audit clients of listed companies in the same industry.

2. Investor protection capabilities

Gongzhengtianye has accrued an occupational risk fund of RMB 891,000, and the cumulative compensation limit of the purchased occupational insurance is RMB 100 million. The accrual of the occupational risk fund and the purchase of occupational insurance comply with relevant regulations. The relevant occupational insurance can Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

Enough to cover civil liability for compensation resulting from audit failure. In the past three years (the last three complete calendar years and the current year), the matters that have been civilly liable in relevant civil lawsuits due to professional conduct are: In the securities misrepresentation liability dispute case of Shanghai Hongda New Materials Co., Ltd., Gongzheng Tianye was judged to be jointly and severally liable for compensation within the scope of 20%.

3. Integrity record

In the past three years, Notary Tianye has been subject to 3 administrative penalties, 6 supervisory and management measures, 3 self-regulatory supervisory measures, and 3 disciplinary sanctions due to professional practices. There has been no criminal penalty due to professional practices.

In the past three years, 22 practitioners have been subject to supervisory and management measures 6 times, self-regulatory measures 4 times, and disciplinary sanctions 3 times due to the practice of Notary Tianye. 15 practitioners have been subject to administrative penalties once each, and 1 practitioner has been subject to administrative penalties twice. There has been no criminal penalty due to professional practices.

This proposal is invited to be reviewed by shareholders and shareholders’ agents.

Board of Directors of Jidan Biotechnology Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Jidan Biotechnology Co., Ltd. on May 22, 2026

Proposal 9:

Proposal on formulating corporate governance related systems

(This proposal was reviewed and approved at the 11th meeting of the company’s fourth session of the Board of Directors held on April 29, 2026.

For details, please refer to the relevant content disclosed by the company on April 30, 2026)

Dear shareholders and shareholders’ agents:

In order to further improve the remuneration management of the company's directors and senior managers, in accordance with the "Company Law of the People's Republic of China", "Listed Company Governance Code" and other relevant laws and regulations and the provisions of the "Articles of Association", and in light of the company's actual situation, the company plans to formulate a "Remuneration Management System for Directors and Senior Managers". For details, please see Appendix 1: "Jidan Biotech: Remuneration Management System for Directors and Senior Management."

This proposal is invited to be reviewed by shareholders and shareholders’ agents.

Board of Directors of Jidan Biotechnology Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Jidan Biotechnology Co., Ltd. on May 22, 2026

Attachment 1: "Jidan Biotech: Remuneration Management System for Directors and Senior Management"

Jidan Biotechnology Co., Ltd.

Remuneration Management System for Directors and Senior Management

Chapter 1 General Provisions

Article 1 In order to further establish and improve the governance system of Jidan Biotechnology Co., Ltd. (hereinafter referred to as the "Company"), standardize and optimize the management of the remuneration of directors and senior managers, in accordance with the Company Law of the People's Republic of China (hereinafter referred to as the "Company Law"), the Securities and Exchange Commission of the People's Republic of China This system is formulated in accordance with the relevant provisions of laws, regulations, normative documents such as the Securities Law (hereinafter referred to as the "Securities Law"), the "Code of Governance of Listed Companies" and the Articles of Association of Jidan Biotechnology Co., Ltd. (hereinafter referred to as the "Articles of Association"), and in combination with the actual development needs of the company.

Article 2 This system applies to company directors (including independent directors) and senior managers stipulated in the Articles of Association.

Article 3 The remuneration of the company’s directors and senior managers shall be consistent with market development, match the company’s operating performance and personal performance, and coordinate with the company’s sustainable development. The company reasonably determines the remuneration distribution ratio of directors, senior managers and ordinary employees based on industry level, development strategy, job value and other factors.

Chapter 2 Remuneration Management Organization

Article 4 The company's shareholders' meeting is responsible for reviewing the remuneration of directors, and the company's board of directors is responsible for reviewing the remuneration of senior managers.

Article 5 The Nomination, Remuneration and Appraisal Committee of the company’s board of directors is responsible for formulating and conducting assessments for directors and senior managers, formulating and reviewing remuneration policies and plans such as the salary decision mechanism, decision-making process, salary payment and stop-payment recourse arrangements for directors and senior managers, and making recommendations to the board of directors on the following matters:

(1) Remuneration of directors and senior managers;

(2) Formulate or change equity incentive plans and employee stock ownership plans, and ensure that incentive objects are granted rights and the conditions for exercising their rights are met;

(3) Directors and senior managers arrange shareholding plans for the subsidiaries to be spun off;

(4) Other matters stipulated by laws, administrative regulations, China Securities Regulatory Commission and the company's articles of association.

Article 6 The Board of Directors or the Nomination, Remuneration and Appraisal Committee shall evaluate individual directors or discuss the 2025 Annual Shareholders Meeting Materials of Jidan Biotechnology Co., Ltd.

The director shall recuse himself from the remuneration.

Article 7 The relevant functional departments of the company shall cooperate with the nomination, remuneration and assessment committee of the board of directors in the specific implementation, execution and assessment of the remuneration plan for the company's directors and senior managers.

Chapter 3 Salary Structure and Payment

Article 8 The independent directors of the company receive independent director allowances from the company, which are paid quarterly. Otherwise, they do not receive other remuneration, social security benefits, etc. from the company.

Article 9 The remuneration of the company's non-independent directors and senior managers consists of basic salary, performance salary and medium- and long-term incentive income. In principle, the proportion of performance salary should not be less than 50% of the total basic salary and performance salary.

The determination and payment of performance-based remuneration and medium- and long-term incentive income for non-independent directors and senior managers of the company should be based on performance evaluation. A certain proportion of performance-based remuneration for non-independent directors and senior managers will be paid after the disclosure of the annual report and performance evaluation. Performance evaluation should be based on audited financial data.

Article 10 All salaries paid by the company are pre-tax amounts. The company withholds and pays personal income tax from wages and bonuses in accordance with relevant national and company regulations.

Article 11 When conducting internal control audits, accounting firms shall focus on the effectiveness of performance evaluation controls and whether salary payments comply with internal control requirements.

Article 12 If a company turns from profit to loss or its losses expand compared with the previous fiscal year, and the average performance remuneration of directors and senior managers does not decrease accordingly, the reasons shall be disclosed.

Chapter 4 Stop Payment and Recourse

Article 13 If the positions of directors and senior managers of the company change due to election, appointment, resignation during the term, etc., their remuneration shall be calculated and paid based on their actual term of office.

Article 14 If any of the following circumstances occurs to the company’s directors and senior managers during their term of office, the company has the right to reduce their salary or not issue performance bonuses:

(1) Seriously violates the Articles of Association and other rules and regulations of the company and is publicly criticized or punished;

(2) Being publicly held accountable by the stock exchange or declared as an inappropriate candidate;

(3) Being administratively punished by the China Securities Regulatory Commission for major securities violations;

(4) Seriously harming the company’s interests or causing significant economic losses to the company;

(5) Violation of laws and regulations or dereliction of duty or dereliction of duty, resulting in major decision-making errors, major safety and liability accidents, serious impact on the company or loss of company assets.

Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

Article 15 The Nomination, Remuneration and Appraisal Committee of the Company’s Board of Directors shall, under the authorization of the Board of Directors, evaluate whether it is necessary to initiate a recovery and deduction procedure for performance remuneration and medium- and long-term incentive income for specific directors and senior managers.

Article 16 When a company retrospectively restates its financial report due to financial fraud or other misstatements, it shall promptly reassess the performance remuneration and medium- and long-term incentive income of directors and senior managers and recover the excess payment accordingly.

Article 17 If a company's directors or senior managers violate their obligations and cause losses to the company, or are at fault for financial fraud, misappropriation of funds, illegal guarantees and other illegal activities, the company shall reduce or stop paying unpaid performance remuneration and medium- and long-term incentive income according to the severity of the case, and recover all or part of the performance remuneration and medium- and long-term incentive income that have been paid during the period when the relevant behavior occurred.

Chapter 5 Salary Adjustment

Article 18 The remuneration system for directors and senior managers should serve the company's development strategy and can be adjusted accordingly as the company's development and external operating conditions change.

Article 19 The basis for adjusting the remuneration of the company’s directors and senior managers is:

(1) Changes in the company’s development strategy and operating environment;

(2) The company’s operating performance;

(3) Changes in market salary levels;

(4) Individual adjustments due to organizational structure adjustments or changes in positions;

(5) Other situations where the company's board of directors deems it necessary to make salary adjustments.

Chapter 6 Supplementary Provisions

Article 20 Matters not covered in this system shall be implemented in accordance with the relevant national laws, regulations and the company's articles of association; if this system conflicts with laws and regulations promulgated by the country in the future or the company's articles of association after being modified through legal procedures, the relevant national laws, regulations and the company's articles of association shall be implemented.

Article 21 The Board of Directors is responsible for formulating, revising and interpreting this system.

Article 22 This system shall come into effect on the day it is passed by the shareholders' meeting, and the same shall apply when it is modified.

Jidan Biotechnology Co., Ltd.

April 2026 Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

Proposal 10:

About the company’s shareholder return plan for the next three years

(2026-2028) Bill

(This proposal was reviewed and approved at the 11th meeting of the company’s fourth session of the Board of Directors held on April 29, 2026.

For details, please refer to the relevant content disclosed by the company on April 30, 2026)

Dear shareholders and shareholders’ agents:

In order to further improve the company's scientific, sustainable and stable dividend decision-making and supervision mechanism, actively reward investors, guide investors to establish long-term investment and rational investment concepts, and form stable return expectations, in accordance with the China Securities Regulatory Commission's "Supervisory Guidelines for Listed Companies No. 3 - Cash Dividends by Listed Companies" and other relevant laws, regulations, normative documents and the "Articles of Association", combined with the company's actual situation, the company's shareholder return plan for the next three years (2026-2028) is specially formulated. For details, please see the attachment. 2: "Shareholder Return Plan for the Next Three Years of Jidan Biotechnology Co., Ltd. (2026-2028)".

This proposal is invited to be reviewed by shareholders and shareholders’ agents.

Board of Directors of Jidan Biotechnology Co., Ltd.

Materials of the 2025 Annual Shareholders Meeting of Jidan Biotechnology Co., Ltd. on May 22, 2026

Attachment 2: "Shareholder Return Plan for the Next Three Years of Jidan Biotechnology Co., Ltd. (2026-2028)"

Jidan Biotechnology Co., Ltd.

Shareholder return planning for the next three years (2026-2028)

In order to further improve the scientific, sustainable and stable dividend decision-making and supervision mechanism of Jidan Biotechnology Co., Ltd. (hereinafter referred to as the "Company"), actively reward investors, guide investors to establish long-term investment and rational investment concepts, and form stable return expectations, in accordance with the China Securities Regulatory Commission's "Regulatory Guidelines for Listed Companies No. 3 - Cash Dividends for Listed Companies" and other relevant laws and regulations, normative documents and the "Articles of Association", combined with the actual situation of the company, the "Shareholder Return Plan for the Next Three Years of Jidan Biotechnology Co., Ltd. (2026- 2028)" (hereinafter referred to as "this plan"), the details are as follows:

1. Factors to consider in formulating this plan

When formulating this plan, the company comprehensively considers the future profit scale, cash flow status, development stage and plan, capital needs, social capital costs and other actual conditions of the company's operation and development and the external environment, balances the reasonable return on investment of shareholders and the company's long-term development, and makes institutional arrangements for the company's profit distribution to ensure the continuity and stability of profit distribution.

2. Principles for formulating this plan

The formulation of this plan should comply with relevant laws, regulations, normative documents and the relevant provisions on profit distribution in the Articles of Association. The company implements a proactive profit distribution policy, attaches great importance to reasonable investment returns for investors, and maintains continuity and stability. During the decision-making and demonstration process of the profit distribution policy, the company's board of directors and shareholders' meeting should communicate with independent directors and small and medium-sized shareholders, fully listen to the opinions and demands of independent directors and public investors, and determine a reasonable profit distribution plan.

3. Shareholder return planning for the next three years (2026-2028)

(1) Form and interval of profit distribution

Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

The company distributes dividends in the form of cash, stocks, or a combination of cash and stocks, and gives priority to cash distribution of profits. If conditions permit, the company may make mid-term profit distributions. In principle, the company distributes cash dividends once a year, and the company's board of directors may propose mid-term cash dividends based on the company's profitability and capital needs.

(2) Conditions and proportions of profit distribution

1. Specific conditions and proportions of the company’s cash dividends:

If there are no major investment plans or major cash expenditures, the company will distribute dividends in cash if the company is profitable for the year and the accumulated undistributed profits are positive. The profits distributed in cash every year shall not be less than 10% of the distributable profits realized in the current year. The company's cumulative profits distributed in cash in the past three years shall not be less than 30% of the average annual distributable profits achieved in the past three years.

A major investment plan or major cash expenditure refers to one of the following situations:

(1) The company’s cumulative expenditure on external investments, asset purchases and other transactions planned in the next twelve months reaches or exceeds 50% of the company’s latest audited net assets, and exceeds 50 million yuan;

(2) The company’s cumulative expenditure on external investments, asset purchases and other transactions planned in the next twelve months will reach or exceed 50% of the company’s most recent audited total assets.

Major investment plans or major cash expenditures must be approved by the company's board of directors and submitted to the shareholders' meeting for review and approval.

2. Specific conditions for the company to issue stock dividends:

When the company's operating conditions are good and the board of directors believes that the company's stock price does not match the company's share capital and that issuing stock dividends is beneficial to the overall interests of all shareholders of the company, it may propose a stock dividend distribution plan provided that the above conditions for cash dividends are met.

(3) Differentiated dividend policy

The company's board of directors should comprehensively consider factors such as the characteristics of the industry, development stage, own business model, profitability level, and whether there are major capital expenditure arrangements, distinguish the following situations, and propose differentiated cash dividend policies in accordance with the procedures stipulated in the articles of association:

(1) If the company is in a mature development stage and has no major capital expenditure arrangements, when distributing profits, the proportion of cash dividends in this profit distribution should be at least 80%;

(2) If the company is in a mature stage of development and has major capital expenditure arrangements, when distributing profits, the proportion of cash dividends in this profit distribution should be at least 40%;

Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

(3) If the company is in the growth stage and has major capital expenditure arrangements, when distributing profits, the proportion of cash dividends in the profit distribution should be at least 20%.

If the company's development stage is difficult to distinguish but there are major capital expenditure arrangements, it can be handled in accordance with the provisions of the preceding paragraph.

(4) Review procedures for the company’s profit distribution plan

1. The company's profit distribution plan is proposed by the board of directors. After the company's board of directors has reviewed and approved the profit distribution plan, the profit distribution plan can be submitted to the shareholders' meeting for review. When the board of directors considers the profit distribution plan, it must be approved by a majority vote of all directors.

2. The company's audit committee shall review the profit distribution policy formulated by the board of directors and pass it by more than half of all members.

3. When the shareholders' meeting considers the profit distribution plan, it should be approved by more than 2/3 of the voting rights held by shareholders attending the shareholders' meeting. At the same time, the company should provide convenience for small and medium-sized shareholders to participate in the shareholders' meeting through online voting and other methods, and fully listen to the opinions and demands of small and medium-sized shareholders.

(5) Implementation of the company’s profit distribution plan

After the company's shareholders make a resolution on the profit distribution plan, or the company's board of directors formulates a specific plan based on the next year's interim dividend conditions and upper limit reviewed and approved by the annual shareholders' meeting, the distribution of dividends (or shares) must be completed within 2 months.

(6) The formulation cycle and adjustment mechanism of shareholder return planning

1. In the event of force majeure such as war or natural disaster, or changes in the company's external operating environment that have a significant impact on the company's production and operations, or the company's own operating conditions undergo major changes, the company may adjust its profit distribution policy.

2. When the company adjusts its profit distribution policy, the board of directors should make a special discussion, demonstrate the reasons for the adjustment in detail, form a written argumentation report and submit it to the shareholders' meeting for review; when the shareholders' meeting considers the proposal, it should be approved by more than 2/3 of the voting rights held by shareholders attending the shareholders' meeting. At the same time, the company should provide investors with online voting methods.

3. The company shall re-examine the shareholder return plan at least every three years, fully consider and listen to the opinions of shareholders (especially small and medium shareholders) and independent directors through multiple channels, and make appropriate and necessary modifications to the company's ongoing dividend distribution policy to determine the shareholder return plan for that period.

4. The company encourages small and medium-sized investors and institutional investors to actively participate in the company's decision-making on profit distribution matters. Before the company's shareholders review the specific profit distribution plan, they should fully listen to the opinions and demands of small and medium-sized shareholders and respond to issues of concern to small and medium-sized shareholders in a timely manner.

Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

4. Matters not covered in this plan shall be implemented in accordance with relevant laws, regulations, normative documents and the Articles of Association. This plan will be interpreted by the company's board of directors and will be implemented from the date of review and approval by the company's shareholders' meeting.

Board of Directors of Jidan Biotechnology Co., Ltd.

April 29, 2026 Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

Among the report items listened to:

"2025 Independent Directors' Work Report"

(Reporter: Wansuiren)

(This proposal was reviewed and approved at the 11th meeting of the company’s fourth session of the Board of Directors held on April 29, 2026.

For details, please refer to the relevant content disclosed by the company on April 30, 2026)

Dear shareholders and shareholders’ agents:

As an independent director of Jidan Biotechnology Co., Ltd. (hereinafter referred to as the "Company"), during my tenure, I strictly followed the requirements of the "Company Law of the People's Republic of China", "Measures for the Administration of Independent Directors of Listed Companies" and other laws and regulations, normative documents and the "Articles of Association". In the work in 2025, in line with the principles of objectivity, fairness and independence, we will perform the duties of independent directors diligently, conscientiously, honestly and independently, take the initiative to understand the company's business operations, actively attend relevant meetings, carefully review various proposals, and prudently express opinions on major company matters. We will give full play to the independent and professional role of independent directors and effectively safeguard the overall interests of the company and the legitimate rights and interests of all shareholders, especially small and medium shareholders. I now report on my performance of my duties as an independent director in 2025 as follows:

1. Basic information of independent directors

(1) Basic situation

Mr. Wan Suiren, Chinese nationality, without permanent residence abroad, was born in 1953. He is a Ph.D. and professor in electronics. He has won four second and third prizes of Jiangsu Province Science and Technology Progress Awards. He once served as an associate professor at the Southeast University Medical College, a visiting scientist at the MIT Institute of Electronics in the United States, and the director of the BME Teaching Steering Committee for Higher Education Institutions under the Ministry of Education from 2013 to 2017. He once served as the vice chairman of the Chinese Biomedical Engineering Society and the chairman of the Medical Artificial Intelligence Branch of the Chinese Biomedical Engineering Society. He is currently a professor at the Southeast University Medical College, the first fellow of the Chinese Biomedical Engineering Society, an independent director of Jiangsu Yuyue Medical Equipment Co., Ltd., an independent director of Nanwei Medical Technology Co., Ltd., and an independent director of the company.

(2) Explanation of whether there are circumstances affecting independence

During the reporting period, I do not hold any position in the company except as an independent director. My immediate family members and major social relations do not hold positions in the company or its affiliated companies. I and my immediate family members do not directly or indirectly hold 1% or more of the company's issued shares. I am not one of the top ten shareholders of the company. I do not hold any position in a shareholder unit that directly or indirectly holds 5% or more of the company's issued shares, and I do not work in the top five shareholder units of the company. I am Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

It has not provided financial, legal, management consulting, technical consulting and other services to the company or its affiliated enterprises; it has not obtained additional, undisclosed other benefits from the company, its major shareholders or interested institutions and personnel. There are no circumstances that affect the independence of independent directors, and it complies with the relevant requirements for the independence of independent directors in laws and regulations such as the "Administrative Measures for Independent Directors of Listed Companies", "Stock Listing Rules of the Shanghai Stock Exchange", "Self-Regulatory Guidelines for Listed Companies of the Shanghai Stock Exchange No. 1 - Standardized Operations".

2. Annual performance overview of independent directors

(1) Attendance at board of directors and shareholders’ meetings

In 2025, the company held a total of 4 board meetings and 2 shareholders' meetings. My attendance at the meeting is as follows: Participating shareholders’ attendance at the board of directors

Meeting status Director’s last name Is it consecutive?

This year you should participate in the newsletter

Name Personal appearance Entrusted appearance Number of absences Failed to attend in person twice Method of shareholder participation in the board of directors

Number of seats Number of seats Number of times since attending meetings Number of times added

discuss

Wansuiren 4 4 4 0 0 No 2

During the reporting period, I attended all board meetings held by the company. There was no absence or entrustment of other directors to attend the board meeting. The voting on various proposals strictly followed the principles of independence and professionalism, and was based on the stance of protecting the rights and interests of small and medium-sized investors. As an independent director, I make full use of my professional knowledge to provide opinions and decision-making references for the scientific decision-making of the board of directors.

(2) Participation in the work of special committees of the board of directors and special meetings of independent directors

During the reporting period, as a member of the Audit Committee of the Board of Directors, I personally attended 3 meetings of the Audit Committee of the Board of Directors; as a member of the Nomination, Remuneration and Appraisal Committee of the Board of Directors, I personally attended 1 meeting of the Nomination, Remuneration and Appraisal Committee; as an independent director, I personally attended 1 special meeting of independent directors. Adhering to the principle of diligence and responsibility, I faithfully performed my duties as an independent director and the special committees of the board of directors. I voted in favor of all resolutions of the special committees of the board of directors, without any objection or abstention.

(3) Communication with internal audit institutions and accounting firms

During the reporting period, in order to effectively perform the supervision responsibilities, during the company's annual audit and annual report preparation process, I actively communicated with the company's internal audit agency and the annual audit accounting firm, and played an active role in the company's annual audit, audit agency evaluation and renewal; I also discussed and communicated with the accounting firm on the annual audit plan, focus and other matters, supervised the audit progress, ensured that the audit work was timely, accurate, objective and fair, and fulfilled my supervisory responsibilities.

(4) Communication with small and medium-sized shareholders

Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials

During the reporting period, the company maintained communication with small and medium-sized shareholders through performance briefings, phone calls, emails and other channels, and relayed and communicated relevant opinions and suggestions to me. I directly interact and communicate with small and medium-sized shareholders by participating in shareholders' meetings and performance briefings, listen to the demands of small and medium-sized shareholders, fulfill the obligations of independent directors in accordance with laws, regulations, Articles of Association and other relevant regulations and requirements, give full play to the role of independent directors, use my professional knowledge and rich experience to provide more constructive opinions to the company, and effectively safeguard the overall interests of the company and the legitimate rights and interests of all shareholders, especially the majority of small and medium-sized shareholders.

(5) On-site work at the company

During my term of office in 2025, I maintained close contact with the company's management, board secretary and relevant staff through on-site communication, phone calls, emails and other methods. I worked on-site at the company for more than 15 days in 2025. In addition, I take advantage of opportunities such as participating in the board of directors, special committees of the board of directors, special meetings of independent directors, and shareholders’ meetings to conduct on-site inspections of the company, gain an in-depth understanding of the company’s business and development, and keep abreast of the company’s production and operation status, financial status, and implementation of board resolutions. I use professional knowledge to put forward constructive opinions and suggestions on relevant resolutions of the company’s board of directors, and give full play to the role of supervision and guidance.

(6) The company’s cooperation with independent directors

The company's chairman, general manager, board secretary and other senior management personnel maintain regular communication with me, allowing me to keep abreast of the company's production and operations. At the same time, before convening board of directors and related meetings, the company carefully prepared meeting materials and delivered them timely and accurately, fully ensuring my right to know, providing convenience for my work, and actively and effectively cooperating with the work of independent directors. The company provides necessary conditions and support for independent directors to better perform their duties.

3. Matters of focus in annual performance of duties by independent directors

(1) Related transactions that should be disclosed

During the reporting period, the company's related-party transactions were all related to daily operations, met the company's business development needs, and were normal commercial transactions. I believe that the content, decision-making and voting procedures of the company's related-party transactions during the reporting period are in compliance with relevant laws, regulations and the Articles of Association such as the "Company Law of the People's Republic of China", the Securities Law of the People's Republic of China, the "Shanghai Stock Exchange Stock Listing Rules" and the "Articles of Association". The company's related-party transactions comply with the principles of fairness, justice and openness. The transaction pricing is fair and reasonable, conducive to the company's business development, will not affect the company's independence, and will not harm the interests of the company and small and medium-sized shareholders.

(2) Disclosure of financial information and internal control evaluation reports in financial accounting reports and periodic reports

During the reporting period, I evaluated the financial information and internal controls in the company's financial accounting reports and periodic reports. 2025 Annual Shareholders Meeting Materials of Jidan Biotechnology Co., Ltd.

The company has supervised the price report, and the company has prepared and disclosed annual reports, semi-annual reports, quarterly reports and internal control evaluation reports on time. The financial information and internal control evaluations in the company's financial accounting reports and periodic reports are true, complete and accurate, and comply with the requirements of the Accounting Standards for Business Enterprises. There are no major false records, misleading statements or major omissions. The above reports have been reviewed by the company's board of directors, audit committee or shareholders' meeting, and the company's directors and senior managers have signed written review opinions on the periodic reports.

(3) Appointment or dismissal of accounting firms

On April 16, 2025, the fourth meeting of the Audit Committee of the fourth board of directors reviewed and approved the "Proposal on Re-appointment of the Accounting Firm." As a member of the Audit Committee, I believe that Gongzheng Tianye Accounting Firm (Special General Partnership) has the qualifications to engage in securities and futures-related businesses, as well as the professional competence and investor protection capabilities to provide financial report audit services to the company, and can meet the company's requirements for financial report audit work. The relevant procedures for the company's renewal of the audit agency are in compliance with laws, regulations and the relevant provisions of the Articles of Association, and there is no harm to the interests of the company and shareholders, especially small and medium-sized shareholders. On April 29, 2025, the fifth meeting of the fourth board of directors reviewed and approved the "Proposal on Re-appointment of the Accounting Firm".

(4) Remuneration of directors and senior managers

During the reporting period, the company's Nomination, Remuneration and Appraisal Committee carried out its work in strict accordance with the company's "Implementation Rules for the Nomination, Remuneration and Appraisal Committee of the Board of Directors" and reviewed the remuneration results of the company's directors and senior managers. The remuneration of the company's directors and senior managers is based on the salary levels of the industry in which the company operates and is formulated based on the company's specific conditions. It is conducive to mobilizing the work enthusiasm and creativity of the company's directors and senior managers, improving the company's operation and management level, and is conducive to the company's long-term sustainable development without harming the interests of the company and all shareholders.

4. Overall evaluation and suggestions

During the reporting period, as an independent director of the company, with the support and cooperation of the company's management, I strictly followed national laws, regulations and the company's relevant regulations, and based on the principles of objectivity, impartiality and independence, effectively performed the duties of an independent director. I attended the company's board of directors, special committees of the board of directors, special meetings of independent directors and shareholders' meetings with a serious attitude. I expressed my opinions prudently, worked diligently and fulfilled my responsibilities, fully exerted the functions and role of an independent director, and safeguarded the overall interests of the company and the legitimate rights and interests of shareholders.

In 2026, I will continue to uphold the spirit of diligence, seriousness and prudence, abide by relevant laws, regulations and rules, effectively perform the duties of an independent director, continue to study relevant laws and regulations, have an in-depth understanding of the company's production operations and operations, continue to make suggestions for the company's development, and promote the company's steady development and establish a good company. 2025 Annual Shareholders' Meeting Materials of Egg Biotechnology Co., Ltd.

play a positive role.

Independent Director of Jidan Biotechnology Co., Ltd.: Wan Suiren

Materials of the 2025 Annual Shareholders Meeting of Jidan Biotechnology Co., Ltd. on May 22, 2026

Among the report items listened to:

"2025 Independent Directors' Work Report"

(Reporter: Ju Jixian)

(This proposal was reviewed and approved at the 11th meeting of the company’s fourth session of the Board of Directors held on April 29, 2026.

For details, please refer to the relevant content disclosed by the company on April 30, 2026)

Dear shareholders and shareholders’ agents:

As an independent director of Jidan Biotechnology Co., Ltd. (hereinafter referred to as the "Company"), during my tenure, I strictly followed the requirements of the "Company Law of the People's Republic of China", "Measures for the Administration of Independent Directors of Listed Companies" and other laws and regulations, normative documents and the "Articles of Association". In the work in 2025, in line with the principles of objectivity, fairness and independence, we will perform the duties of independent directors diligently, conscientiously, honestly and independently, take the initiative to understand the company's business operations, actively attend relevant meetings, carefully review various proposals, and prudently express opinions on major company matters. We will give full play to the independent and professional role of independent directors and effectively safeguard the overall interests of the company and the legitimate rights and interests of all shareholders, especially small and medium shareholders. I now report on my performance of my duties as an independent director in 2025 as follows:

1. Basic information of independent directors

(1) Basic situation

Mr. Ju Jixian, Chinese nationality, no permanent residence abroad, born in 1964, Doctor of Science, professor, doctoral supervisor. From 1996 to 1997, he was a postdoctoral fellow at the University of Montreal in Canada. In 1999, he was appointed as a professor at Nanjing University. In 2003, he received the National Science Fund for Distinguished Young Scholars. In 2007, he was a distinguished professor of the "Changjiang Scholars" of the Ministry of Education and a national candidate for the "New Century Hundreds and Thousands of Talents Project". He was the chief scientist of the "973" project in 2011. He is currently the director of the National Key Laboratory of Analytical Chemistry of Life at Nanjing University, a fellow of the International Electrochemical Society, a fellow of the Royal Society of Chemistry, a fellow of the Chinese Chemical Society, and an independent director of the company.

(2) Explanation of whether there are circumstances affecting independence

During the reporting period, I do not hold any position in the company except as an independent director. My immediate family members and major social relations do not hold positions in the company or its affiliated enterprises. I and my immediate family members do not directly or indirectly hold 1% or more of the company’s issued shares. I am not one of the top ten shareholders of the company, and do not directly or indirectly hold the company’s issued shares. I hold positions in 5% or more of the shareholder units and do not work in the top five shareholder units of the company. I have not provided financial, legal, management consulting, technical consulting and other services to the company or its affiliated enterprises; I have not obtained the 2025 Annual Shareholders Meeting Materials from Gongjidan Biotechnology Co., Ltd.

The company and its major shareholders or interested institutions and personnel have obtained additional, undisclosed other interests. There are no circumstances that affect the independence of independent directors, and it complies with the relevant requirements for the independence of independent directors in laws and regulations such as the "Administrative Measures for Independent Directors of Listed Companies", "Stock Listing Rules of the Shanghai Stock Exchange", "Self-Regulatory Guidelines for Listed Companies of the Shanghai Stock Exchange No. 1 - Standardized Operations".

2. Annual performance overview of independent directors

(1) Attendance at board of directors and shareholders’ meetings

In 2025, the company held a total of 4 board meetings and 2 shareholders' meetings. My attendance at the meeting is as follows: Participating shareholders’ attendance at the board of directors

meeting situation

Yes No Connect

Director's last name

You should participate in the newsletter twice this year

Name Personal appearance Entrusted appearance Absence times Attend shareholder plus board of directors method Participation Not in person

Number of seats Number of seats Number of meetings Number of meetings Added number of meetings attended

discuss

Ju Jixian 4 4 4 0 0 No 2

During the reporting period, I attended all board meetings held by the company. There was no absence or entrustment of other directors to attend the board meeting. The voting on various proposals strictly followed the principles of independence and professionalism, and was based on the stance of protecting the rights and interests of small and medium-sized investors. As an independent director, I make full use of my professional knowledge to provide opinions and decision-making references for the scientific decision-making of the board of directors.

(2) Participation in the work of special committees of the board of directors and special meetings of independent directors

During the reporting period, as a member of the Nomination, Remuneration and Appraisal Committee of the Board of Directors, I personally attended 1 meeting of the Nomination, Remuneration and Appraisal Committee of the Board of Directors; as a member of the Strategy Committee, I personally attended 1 meeting of the Strategy Committee; as an independent director, I personally attended 1 special meeting of independent directors. I adhere to the principle of diligence and responsibility, faithfully perform my duties as an independent director and a member of the special committees of the board of directors, and vote in favor of all resolutions of the special committees of the board of directors and special meetings of independent directors, without any objection or abstention.

(3) Communication with internal audit institutions and accounting firms

In the process of reviewing the company's regular reports, I pay attention to the company's key issues during the reporting period and actively communicate with the company's internal audit agency and annual audit accounting firm.

(4) Communication with small and medium-sized shareholders

During the reporting period, the company maintained communication with small and medium-sized shareholders through performance briefings, phone calls, emails and other channels, and relayed and communicated relevant opinions and suggestions to me. I directly interacted and communicated with small and medium-sized shareholders by participating in shareholders' meetings and performance briefings, listened to the demands of small and medium-sized shareholders, and acted in accordance with laws and regulations, the "Articles of Association" and other relevant Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders' Meeting Materials

regulations and requirements, fulfill the obligations of independent directors, give full play to the role of independent directors, use their professional knowledge and rich experience to provide more constructive opinions to the company, and effectively safeguard the overall interests of the company and the legitimate rights and interests of all shareholders, especially the majority of small and medium-sized shareholders.

(5) On-site work at the company

During my term of office in 2025, I maintained close contact with the company's management, board secretary and relevant staff through on-site communication, phone calls, emails and other methods. I worked on-site at the company for more than 15 days in 2025. In addition, I take advantage of opportunities such as participating in the board of directors, special committees of the board of directors, special meetings of independent directors, and shareholders’ meetings to conduct on-site inspections of the company, gain an in-depth understanding of the company’s business and development, and keep abreast of the company’s production and operation status, financial status, and implementation of board resolutions. I use professional knowledge to put forward constructive opinions and suggestions on relevant resolutions of the company’s board of directors, and give full play to the role of supervision and guidance.

(6) The company’s cooperation with independent directors

The company's chairman, general manager, board secretary and other senior management personnel maintain regular communication with me, allowing me to keep abreast of the company's production and operations. At the same time, before convening board of directors and related meetings, the company carefully prepared meeting materials and delivered them timely and accurately, fully ensuring my right to know, providing convenience for my work, and actively and effectively cooperating with the work of independent directors. The company provides necessary conditions and support for independent directors to better perform their duties.

3. Matters of focus in annual performance of duties by independent directors

(1) Related transactions that should be disclosed

During the reporting period, the company's related-party transactions were all related to daily operations, met the company's business development needs, and were normal commercial transactions. I believe that the content, decision-making and voting procedures of the company's related-party transactions during the reporting period are in compliance with relevant laws, regulations and the Articles of Association such as the "Company Law of the People's Republic of China", the Securities Law of the People's Republic of China, the "Shanghai Stock Exchange Stock Listing Rules" and the "Articles of Association". The company's related-party transactions comply with the principles of fairness, justice and openness. The transaction pricing is fair and reasonable, conducive to the company's business development, will not affect the company's independence, and will not harm the interests of the company and small and medium-sized shareholders.

(2) Disclosure of financial information and internal control evaluation reports in financial accounting reports and periodic reports

During the reporting period, I supervised the financial information and internal control evaluation reports in the company's financial accounting reports and periodic reports. The company prepared and disclosed annual reports, semi-annual reports, quarterly reports and internal control evaluation reports on time. The financial information and internal control evaluation reports in the company's financial accounting reports and periodic reports are true, complete and accurate, and meet the requirements of corporate accounting standards. There are no major false records, misleading statements or materials for the 2025 Annual Shareholders Meeting of Jidan Biotechnology Co., Ltd.

Major omissions. The above reports have been reviewed by the company's board of directors or shareholders' meeting, and the company's directors and senior managers have signed written review opinions on the periodic reports.

(3) Appointment or dismissal of accounting firms

On April 29, 2025, the fifth meeting of the fourth board of directors reviewed and approved the "Proposal on Re-appointment of the Accounting Firm", and I voted in favor of the proposal.

(4) Remuneration of directors and senior managers

During the reporting period, the company's Nomination, Remuneration and Appraisal Committee carried out its work in strict accordance with the company's "Implementation Rules for the Nomination, Remuneration and Appraisal Committee of the Board of Directors" and reviewed the remuneration results of the company's directors and senior managers. The remuneration of the company's directors and senior managers is based on the salary levels of the industry in which the company operates and is formulated based on the company's specific conditions. It is conducive to mobilizing the work enthusiasm and creativity of the company's directors and senior managers, improving the company's operation and management level, and is conducive to the company's long-term sustainable development without harming the interests of the company and all shareholders.

4. Overall evaluation and suggestions

During the reporting period, as an independent director of the company, with the support and cooperation of the company's management, I strictly followed national laws, regulations and the company's relevant regulations, and based on the principles of objectivity, impartiality and independence, effectively performed the duties of an independent director. I attended the company's board of directors, special committees of the board of directors, special meetings of independent directors and shareholders' meetings with a serious attitude. I expressed my opinions prudently, worked diligently and fulfilled my responsibilities, fully exerted the functions and role of an independent director, and safeguarded the overall interests of the company and the legitimate rights and interests of shareholders.

In 2026, I will continue to uphold the spirit of diligence, seriousness and prudence, abide by relevant laws, regulations and rules, effectively perform the duties of an independent director, continue to study relevant laws and regulations, have an in-depth understanding of the company's production operations and operations, continue to provide suggestions for the company's development, and play an active role in promoting the company's steady development and establishing a good image of the company.

Independent Director of Jidan Biotechnology Co., Ltd.: Ju Jixian

Materials of the 2025 Annual Shareholders Meeting of Jidan Biotechnology Co., Ltd. on May 22, 2026

Among the report items listened to:

"Company's 2025 Independent Directors' Work Report"

(Reporter: Ling Hua)

(This proposal was reviewed and approved at the 11th meeting of the company’s fourth session of the Board of Directors held on April 29, 2026.

For details, please refer to the relevant content disclosed by the company on April 30, 2026)

Dear shareholders and shareholders’ agents:

As an independent director of Jidan Biotechnology Co., Ltd. (hereinafter referred to as the "Company"), during my tenure, I strictly followed the requirements of the "Company Law of the People's Republic of China", "Measures for the Administration of Independent Directors of Listed Companies" and other laws and regulations, normative documents and the "Articles of Association". In the work in 2025, in line with the principles of objectivity, fairness and independence, we will perform the duties of independent directors diligently, conscientiously, honestly and independently, take the initiative to understand the company's business operations, actively attend relevant meetings, carefully review various proposals, and prudently express opinions on major company matters. We will give full play to the independent and professional role of independent directors and effectively safeguard the overall interests of the company and the legitimate rights and interests of all shareholders, especially small and medium shareholders. I now report on my performance of my duties as an independent director in 2025 as follows:

1. Basic information of independent directors

(1) Basic situation

Ms. Ling Hua, Chinese nationality, no permanent residence abroad, born in 1981, Ph.D. in Management, associate professor. In July 2010, he worked at the Accounting School of Nanjing Audit University. He is currently the deputy dean of the Accounting School of Nanjing Audit University, an independent director of Nanjing Maolai Optical Technology Co., Ltd., an independent director of Suzhou Sudaweige Technology Group Co., Ltd., and an independent director of the company.

(2) Explanation of whether there are circumstances affecting independence

During the reporting period, I do not hold any position in the company except as an independent director. My immediate family members and major social relations do not hold positions in the company or its affiliated enterprises. I and my immediate family members do not directly or indirectly hold 1% or more of the company’s issued shares. I am not one of the top ten shareholders of the company, and do not directly or indirectly hold the company’s issued shares. I hold positions in 5% or more of the shareholder units and do not work in the top five shareholder units of the company. I have not provided financial, legal, management consulting, technical consulting and other services to the company or its affiliated enterprises; I have not obtained additional, undisclosed other benefits from the company and its major shareholders or interested institutions and personnel. There are no circumstances that affect the independence of independent directors, and it complies with the "Administrative Measures for Independent Directors of Listed Companies" and "Shanghai Securities Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders Meeting Materials"

The relevant requirements for the independence of independent directors in laws and regulations such as the Stock Exchange Listing Rules and the Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operations.

2. Annual performance overview of independent directors

(1) Attendance at board of directors and shareholders’ meetings

In 2025, the company held a total of 4 board meetings and 2 shareholders' meetings. My attendance at the meeting is as follows: Participating shareholders’ attendance at the board of directors

meeting situation

Yes No Connect

director

Continued twice by communication

Name Should participate this year In person Out by proxy Out absent in times Attended by shareholders Oriental style Participation Not in person

Number of Board of Directors Number of seats Number of seats Number of meetings plus number of meetings attended

discuss

ADLINK 4 4 4 0 0 No 2

During the reporting period, I attended all board meetings held by the company. There was no absence or entrustment of other directors to attend the board meeting. The voting on various proposals strictly followed the principles of independence and professionalism, and was based on the stance of protecting the rights and interests of small and medium-sized investors. As an independent director, I make full use of my professional knowledge to provide opinions and decision-making references for the scientific decision-making of the board of directors.

(2) Participation in the work of special committees of the board of directors and special meetings of independent directors

During the reporting period, as a member of the Audit Committee of the Board of Directors, I personally attended three audit committee meetings; as an independent director, I personally attended one special meeting of independent directors. I adhere to the principle of diligence and responsibility, faithfully perform my duties as an independent director and a member of the special committees of the board of directors, and vote in favor of all resolutions of the special committees of the board of directors and special meetings of independent directors, without any objection or abstention.

(3) Communication with internal audit institutions and accounting firms

During the reporting period, in order to effectively perform the supervision responsibilities, during the company's annual audit and annual report preparation process, I actively communicated with the company's internal audit agency and the annual audit accounting firm, and played an active role in the company's annual audit, audit agency evaluation and renewal; I also discussed and communicated with the accounting firm on the annual audit plan, focus and other matters, supervised the audit progress, ensured that the audit work was timely, accurate, objective and fair, and fulfilled my supervisory responsibilities.

(4) Communication with small and medium-sized shareholders

During the reporting period, the company maintained communication with small and medium-sized shareholders through performance briefings, phone calls, emails and other channels, and relayed and communicated relevant opinions and suggestions to me. I directly interacted and communicated with small and medium-sized shareholders by participating in shareholders' meetings and performance briefings, listened to the demands of small and medium-sized shareholders, and acted in accordance with laws and regulations, the "Articles of Association" and other relevant Jidan Biotechnology Co., Ltd. 2025 Annual Shareholders' Meeting Materials

regulations and requirements, fulfill the obligations of independent directors, give full play to the role of independent directors, use their professional knowledge and rich experience to provide more constructive opinions to the company, and effectively safeguard the overall interests of the company and the legitimate rights and interests of all shareholders, especially the majority of small and medium-sized shareholders.

(5) On-site work at the company

During my term of office in 2025, I maintained close contact with the company's management, board secretary and relevant staff through on-site communication, phone calls, emails and other methods. I worked on-site at the company for more than 15 days in 2025. In addition, I take advantage of opportunities such as participating in the board of directors, special committees of the board of directors, special meetings of independent directors, and shareholders’ meetings to conduct on-site inspections of the company, gain an in-depth understanding of the company’s business and development, and keep abreast of the company’s production and operation status, financial status, and implementation of board resolutions. I use professional knowledge to put forward constructive opinions and suggestions on relevant resolutions of the company’s board of directors, and give full play to the role of supervision and guidance.

(6) The company’s cooperation with independent directors

The company's chairman, general manager, board secretary and other senior management personnel maintain regular communication with me, allowing me to keep abreast of the company's production and operations. At the same time, before convening board of directors and related meetings, the company carefully prepared meeting materials and delivered them timely and accurately, fully ensuring my right to know, providing convenience for my work, and actively and effectively cooperating with the work of independent directors. The company provides necessary conditions and support for independent directors to better perform their duties.

3. Matters of focus in annual performance of duties by independent directors

(1) Related transactions that should be disclosed

During the reporting period, the company's related-party transactions were all related to daily operations, met the company's business development needs, and were normal commercial transactions. I believe that the content, decision-making and voting procedures of the company's related-party transactions during the reporting period are in compliance with relevant laws, regulations and the Articles of Association such as the "Company Law of the People's Republic of China", the Securities Law of the People's Republic of China, the "Shanghai Stock Exchange Stock Listing Rules" and the "Articles of Association". The company's related-party transactions comply with the principles of fairness, justice and openness. The transaction pricing is fair and reasonable, conducive to the company's business development, will not affect the company's independence, and will not harm the interests of the company and small and medium-sized shareholders.

(2) Disclosure of financial information and internal control evaluation reports in financial accounting reports and periodic reports

During the reporting period, I supervised the financial information and internal control evaluation reports in the company's financial accounting reports and periodic reports. The company prepared and disclosed annual reports, semi-annual reports, quarterly reports and internal control evaluation reports on time. The financial information and internal control evaluation reports in the company's financial accounting reports and periodic reports are true, complete and accurate, and meet the requirements of corporate accounting standards. There are no major false records, misleading statements or materials for the 2025 Annual Shareholders Meeting of Jidan Biotechnology Co., Ltd.

Major omissions. The above reports have been reviewed by the company's board of directors, audit committee or shareholders' meeting, and the company's directors and senior managers have signed written review opinions on the periodic reports.

(3) Appointment or dismissal of accounting firms

On April 16, 2025, the fourth meeting of the Audit Committee of the fourth board of directors reviewed and approved the "Proposal on Re-appointment of the Accounting Firm." As a member of the Audit Committee, I believe that Gongzheng Tianye Accounting Firm (Special General Partnership) has the qualifications to engage in securities and futures-related businesses, as well as the professional competence and investor protection capabilities to provide financial report audit services to the company, and can meet the company's requirements for financial report audit work. The relevant procedures for the company's renewal of the audit agency are in compliance with laws, regulations and the relevant provisions of the Articles of Association, and there is no harm to the interests of the company and shareholders, especially small and medium-sized shareholders. On April 29, 2025, the fifth meeting of the fourth board of directors reviewed and approved the "Proposal on Re-appointment of the Accounting Firm".

(4) Remuneration of directors and senior managers

During the reporting period, the company's board of directors reviewed and approved the "Proposal on the Remuneration of the Company's Directors and Senior Management Personnel" and reviewed the remuneration results of the company's directors and senior management personnel. The remuneration of the company's directors and senior managers is based on the salary levels of the industry in which the company operates and the company's specific circumstances. It is conducive to mobilizing the work enthusiasm and creativity of the company's directors and senior managers, improving the company's operation and management level, and is conducive to the company's long-term sustainable development.

4. Overall evaluation and suggestions

During the reporting period, as an independent director of the company, with the support and cooperation of the company's management, I strictly followed national laws, regulations and the company's relevant regulations, and based on the principles of objectivity, impartiality and independence, effectively performed the duties of an independent director. I attended the company's board of directors, special committees of the board of directors, special meetings of independent directors and shareholders' meetings with a serious attitude. I expressed my opinions prudently, worked diligently and fulfilled my responsibilities, fully exerted the functions and role of an independent director, and safeguarded the overall interests of the company and the legitimate rights and interests of shareholders.

In 2026, I will continue to uphold the spirit of diligence, seriousness and prudence, abide by relevant laws, regulations and rules, effectively perform the duties of an independent director, continue to study relevant laws and regulations, have an in-depth understanding of the company's production operations and operations, continue to provide suggestions for the company's development, and play an active role in promoting the company's steady development and establishing a good image of the company.

Independent Director of Jidan Biotechnology Co., Ltd.: Ling Hua

May 22, 2026